# A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

> clinical trial · VERIFIED · 2026-08-14

Status: RECRUITING · Sponsor: Mirati Therapeutics Inc. · Condition: Carcinoma, Non-Small-Cell Lung

- Company: Mirati Therapeutics Inc.
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06875310

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.